Invesaro

Stocks RARE Earnings

Earnings

Ultragenyx Pharmaceutical Inc. (RARE) earnings

Quarterly results of Ultragenyx Pharmaceutical Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when RARE files with the SEC.

Next earnings date

Ultragenyx Pharmaceutical Inc. is expected to report around January 11, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Ultragenyx Pharmaceutical Inc. reported revenue of $173M (+8.1% on the same quarter a year earlier) and a net loss of $118M.

Diluted earnings per share were -$1.16.

Filed with the SEC on November 4, 2026.

Revenue by quarter
Q4 24: $164.6M $164.6M Q4 24Q1 25: $139M $139M Q1 25Q2 25: $167M $167M Q2 25Q3 25: $160M $160M Q3 25Q4 25: $207M $207M Q4 25Q1 26: $136M $136M Q1 26Q2 26: $214M $214M Q2 26Q3 26: $173M $173M Q3 26
Net income by quarter
Q4 24: -$133.2M -$133.2M Q4 24Q1 25: -$151M -$151M Q1 25Q2 25: -$115M -$115M Q2 25Q3 25: -$180M -$180M Q3 25Q4 25: -$129M -$129M Q4 25Q1 26: -$185M -$185M Q1 26Q2 26: -$92M -$92M Q2 26Q3 26: -$118M -$118M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$173M+8.1%-$118M-$1.16
Q2 FY2026June 30, 2026$214M+28.1%-$92M-$0.90
Q1 FY2026March 31, 2026$136M-2.2%-$185M-$1.84
Q4 FY2025December 31, 2025$207M+25.7%-$129M-
Q3 FY2025September 30, 2025$160M--$180M-$1.81
Q2 FY2025June 30, 2025$167M--$115M-$1.17
Q1 FY2025March 31, 2025$139M--$151M-$1.57
Q4 FY2024December 31, 2024$164.6M--$133.2M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Ultragenyx Pharmaceutical Inc.'s next earnings date?

Ultragenyx Pharmaceutical Inc. is expected to report around January 11, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Ultragenyx Pharmaceutical Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, Ultragenyx Pharmaceutical Inc. reported revenue of $173M and a net loss of $118M. The figures come from its filing with the SEC.

Is Ultragenyx Pharmaceutical Inc.'s revenue growing?

Revenue in Q3 FY2026 was $173M, up 8.1% from $160M in the same quarter a year earlier.

Get an email when RARE reports

Follow RARE and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when RARE files with the SEC.

Source: quarterly figures Ultragenyx Pharmaceutical Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Ultragenyx Pharmaceutical Inc.